New year, new tax rates. How did the world’s biggest drugmakers fare?
Biopharma is bursting with reports this month of how Trumpian tax breaks will affect the industry’s biggest players, with AbbVie’s $ABBV jaw-dropping 50% rate slash winning the award for most notable headline. Big Pharma joined the parade shortly thereafter, each touting tax rate projections that equate to big money on the books for 2018.
We collected reports from 13 of the biggest drugmakers affected by the US corporate tax cut — all with revenues in the double-digit billions — to gauge the average impact of the new law on Big Pharma (full list below).
Basic subscription required
Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.